Flash Finance

FDC LimitedFDCCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹356.25
MCap ₹5,800 Cr · P/E 19.7
FDC Limited — Stock analysis & AI research FDC Limited — Seasonality — best & worst months FDC Limited — Technical indicators & charts FDC Limited — Technical setup — score, trend, support & resistance FDC Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 High Promoter Holding Stocks 📈 MACD Bullish Crossover 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹655 Cr
Sales · Jun 2026
+2.0% YoY
₹143 Cr
Operating Profit · Jun 2026
+1.3% YoY
21.8%
OPM % · Jun 2026
-0.9% YoY
₹132 Cr
Net Profit · Jun 2026
+8.2% YoY
₹8.11
EPS · Jun 2026
+8.0% YoY

📝 FDC Limited — results explained

Quarter ended June 2026 (Q1 FY27)

FDC Limited reported revenue of ₹655 crore for the quarter ended June 2026 (Q1 FY27), up 2.0% from ₹642 crore in the same quarter last year, and up 16.2% sequentially over the March 2026 quarter.

Net profit rose 8.2% year-on-year to ₹132 crore, from ₹122 crore. Earnings per share (EPS) came in at ₹8.11.

Operating profit stood at ₹143 crore — an operating margin (OPM) of 21.8%, compared with 22.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, FDC Limited posted revenue of ₹2,126 crore, a growth of 2.7% over FY25, with a net profit of ₹285 crore (up 4.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,139 crore with a net profit of ₹295 crore.

Valuation snapshot

At the current price of ₹356.25, FDC has a market capitalisation of ₹5,800 crore and a trailing P/E of about 19.7.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 9th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 69.65%, foreign institutional investors (FIIs) 2.40%, domestic institutional investors (DIIs) 6.29%, public shareholders 21.65% of FDC Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹5,800 Cr
Current Price ?
₹356.2
P/E ?
19.66below ind
Industry P/E ?
37.20
P/B ?
2.33
P/S ?
2.71
P/FCF ?
145.00
Enterprise Value ?
₹5,815 Cr
EV/EBITDA ?
17.11
PEG ?
1.31
Earnings Yield ?
4.8%
Dividend Yield ?
1.41%
Profitability & Returns
Sales (TTM) ?
₹2,139 Cr
OPM ?
15.9%
Profit after tax (TTM) ?
₹295 Cr
EPS (TTM) ?
₹18.12
ROCE ?
17.0%
ROE ?
11.8%
ROA ?
10.1%
Growth
Sales — latest qtr ?
₹655 Cr
PAT — latest qtr ?
₹132 Cr
YoY qtr sales growth ?
2.0%
YoY qtr profit growth ?
8.2%
Sales growth (3y) ?
6%
Sales growth (5y) ?
10%
Profit growth (3y) ?
15%
Profit growth (5y) ?
2%
Financial Health
Debt ?
₹15 Cr
Debt to Equity ?
0.01
Interest Coverage ?
55.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
69.65%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-15.2%
Return 6 months ?
-0.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 407435530480452454624505459482642462458564655 +2.0% +16.2%
Operating Profit 47491207982581427246531413550112143 +1.3% +27.5%
Other Income 1973027252128351931362114747 +31.5% +0.7%
Interest 111111111111121 -18.0% -59.0%
Depreciation 101010101010111413161515151415 +0.6% +7.8%
Profit Before Tax 54451399596671589250681613935143174 +8.2% +21.9%
Net Profit 39311097278481157436481222927107132 +8.2% +23.4%
EPS 2.381.856.544.364.812.967.064.552.242.967.511.811.676.588.11 +8.0% +23.3%
OPM % 11.4% 11.3% 22.6% 16.4% 18.1% 12.8% 22.7% 14.3% 10.0% 11.0% 22.0% 7.6% 10.9% 19.9% 21.8% -0.9% +9.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,070 Cr ₹2,126 Cr ₹2,139 Cr +2.7%
Operating Profit ₹313 Cr ₹338 Cr ₹340 Cr +8.0%
OPM % 15.12% 15.90% 15.89% +5.2%
NPM % 13.19% 13.41% 13.79% +1.7%
Other Income ₹113 Cr ₹105 Cr ₹116 Cr -6.9%
Depreciation ₹54 Cr ₹59 Cr ₹59 Cr +9.8%
Interest ₹4 Cr ₹5 Cr ₹5 Cr +14.6%
EBIT ₹259 Cr ₹279 Cr ₹281 Cr +7.6%
PBT ₹368 Cr ₹378 Cr ₹391 Cr +2.8%
Tax ₹61 Cr — ₹42 Cr —
Net Profit ₹273 Cr ₹285 Cr ₹295 Cr +4.4%
EPS ₹16.81 ₹17.57 ₹18.17 +4.5%
Material Cost ₹334 Cr — ₹163 Cr —
Employee Cost ₹240 Cr — ₹134 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 17161616 +0.0%
Reserves 1,9642,0812,2712,476 +9.0%
Borrowings 28202115 -28.6%
Other Liabilities 327341402404 +0.5%
Total Liabilities 2,3352,4592,7102,912 +7.5%
Fixed Assets 695676848994 +17.2%
CWIP 19826113696 -29.4%
Investments 8068501,0501,070 +1.9%
Other Assets 637672677752 +11.1%
Total Assets 2,3352,4592,7102,912 +7.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 165221310200 -35.5%
Cash from Investing Activity 4-18-199-109 +45.2%
Cash from Financing Activity -180-202-92-93 -1.1%
Net Cash Flow -11119-2 -110.5%
Free Cash Flow 5415122040 -81.8%
CFO/OP 95%96%129%81% -37.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 25221824 +33.3%
Inventory Days 180217185182 -1.6%
Days Payable 100104102106 +3.9%
Cash Conversion Cycle 106134102100 -2.0%
Working Capital Days 485233123 +272.7%
ROCE % 13%18%16%17% +6.2%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 69.66%69.66%69.66%69.65% -0.0%
FIIs 2.41%2.43%2.32%2.40% +3.4%
DIIs 7.17%6.81%6.27%6.29% +0.3%
Public 20.76%21.10%21.76%21.65% -0.5%
No. of Shareholders 54,44554,15753,78852,730 -2.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was FDC Limited's revenue in Q1 FY27?
FDC Limited reported revenue of ₹655 crore for the quarter ended June 2026 (Q1 FY27), up 2.0% from ₹642 crore in the same quarter last year, and up 16.2% sequentially over the March 2026 quarter.
What was FDC Limited's net profit in Q1 FY27?
Net profit rose 8.2% year-on-year to ₹132 crore, from ₹122 crore. Earnings per share (EPS) came in at ₹8.11.
What is FDC's market capitalisation and P/E ratio?
At the current price of ₹356.25, FDC has a market capitalisation of ₹5,800 crore and a trailing P/E of about 19.7.
Who owns FDC Limited? (shareholding pattern)
As of Mar 2026, promoters held 69.65%, foreign institutional investors (FIIs) 2.40%, domestic institutional investors (DIIs) 6.29%, public shareholders 21.65% of FDC Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI